Business
Appointment of Head of Business Development
ECO Animal Health Group plc announces the appointment of Dr Andrew Winder as Head of Business Development, effective May 11, 2026, to identify strategic growth opportunities for its R&D pipeline. Dr. Winder brings extensive experience from Norbrook Laboratories Ltd, where he secured multiple co-development and distribution agreements and developed a global portfolio strategy that doubled the company's project pipeline. His role will focus on in-licensing partnerships to expand ECO's R&D pipeline, coinciding with the EU commercial launch of its poultry vaccine, ECOVAXXIN® MS. Disclaimer*
About this update from Eco Animal Health Group Plc
[{"type":"text","content":"\n\n14 April 2026\n\n \nECO Animal Health Group plc\n(\"ECO\" or the \"Company\")\n \nAppointment of Head of Business Development\nDr Andrew Winder to identify strategic growth opportunities for ECO's R&D pipeline\n \nECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces the appointment of Dr Andrew Winder as Head of Business Development, effective from 11 May 2026.\n \nAndrew brings extensive strategic business development expertise to ECO, with a proven track record of driving profitable growth across global animal health markets. Andrew most recently served as Strategic Business Development Lead at Norbrook Laboratories Ltd (Norbrook), a global provider of veterinary pharmaceuticals. During his 14-year tenure at Norbrook, Andrew secured multiple co-development and distribution agreements, created a new global portfolio strategy that doubled the number of projects in Norbrook's pipeline, and negotiated distribution agreements with leading multi-national partners including Boehringer Ingelheim, Zoetis and Elanco.\n \nIn his new role, Andrew will be responsible for identifying and securing strategic opportunities, including in-licensing partnerships to grow the Company's R&D pipeline. His appointment comes at a pivotal time as ECO progresses the EU commercial launch of its live vaccine for poultry, ECOVAXXIN® MS, and continues to expand its position as a comprehensive solutions provider in animal health.\n \nAndrew holds a PhD in Pharmaceutical Sciences from the University of Ulster and a BSc (Hons) in Microbiology from Queens University Belfast. He has also served as a member of the Board of Directors for Animal Health Europe.\n \nDavid Hallas, Chief Executive Officer of ECO Animal Health, commented: \"We are delighted to welcome Andrew to ECO. His strategic vision, proven ability to negotiate complex agreements and deep understanding of the animal health landscape make him a valuable addition to our team. As we advance our R&D pipeline and expand our commercial footprint, Andrew's expertise in portfolio management and strategic partnerships will be instrumental in driving our next phase of growth.\"\n \nDr Andrew Winder, newly appointed Head...